Report / Paper metadata
Cost-effectiveness of pembrolizumab plus weekly paclitaxel for PD-L1–positive platinum-resistant recurrent ovarian cancer in the United States and China
A biomedical paper record. This page preserves its title, publication metadata and identifier, not the full article. The title alone does not establish the study findings or their clinical importance.
Limits
No clinical review has been performed. This record is not a treatment recommendation, eligibility confirmation or current availability guarantee.
- Kind
- Paper metadata